Clinical Findings-The pig was moderately anemic, and its abdomen was greatly distended. A freely movable abdominal mass was detected during palpation and ultrasonographic examination of the abdomen. Examination of abdominal and thoracic
radiographs revealed faint, ill-defined, linear and curvilinear mineralized opacities in the region of the mass and that the gastrointestinal tract was displaced craniodorsally. Results of radiographic examination suggested that the cause of distention was a single abdominal mass (possibly a neoplasm).
Treatment and Outcome-Surgery was performed, Selleckchem IPI145 and the mass, which was identified as the right ovary, was removed. The left ovary had a normal appearance, but it was also removed during surgery. The pig was administered a transfusion (314 mL of plasma and 296 mL of packed RBCs) before and during surgery. The mass, which accounted for approximately one-third of the pig’s body
weight, was identified histologically as an ovarian leiomyoma.
Clinical FLT3 inhibitor Relevance-Pigs can safely be administered a transfusion of RBCs and plasma. Ovarian tumors can be removed from Vietnamese potbellied pigs, which allows them to be used as pets or for reproduction when only 1 ovary is affected. Uterine masses in older sexually intact Vietnamese potbellied pigs are more common than are ovarian tumors; thus, complete ovariohysterectomy should be considered when the primary purpose of the pig is to serve as a pet. (J Am Vet Med Assoc 2010;236:558-561)”
“Background PARP signaling and aims: The effects of maintenance infliximab for Crohn’s disease vary widely among patients. The aim of this study was to examine the cytokine profiles and to identify possible markers predictive of therapeutic effect of maintenance infliximab.
Methods: Cytokine profiles of 35 Crohn’s disease patients under maintenance infliximab therapy were analyzed prospectively. Blood samples were obtained prior to, and 2 and 6 weeks after infliximab infusion. Circulating cytokine values of interleukin (IL)-23, IL-17A, IL-12, IL-6, interferon gamma
(IFN-gamma), and tumor necrosis factor alpha (TNF-alpha) were compared according to the disease activity and therapeutic efficacy. Patients were classified into either the active or quiescent phase according to their disease activity at baseline. Patients were also divided into a sustained response group and non-sustained response group according to therapeutic efficacy of infliximab determined 2 and 6 weeks after infliximab infusion.
Results: At baseline, serum levels of IL-23 (p<0.05), IL-17A (p<0.01), IFN-gamma (p<0.05), and IL-6 (p<0.01) were significantly higher in active Crohn’s disease than in quiescent disease. These cytokine levels remained unchanged during the follow-up period.